Testing a daily pill called vorasidenib for IDH-mutant astrocytoma after first treatment
Original title: Vorasidenib Maintenance for IDH Mutant Astrocytoma
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a large late stage trial, but it is still a test and not care your own doctor can give you.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial is testing whether a daily pill can hold off tumor growth longer than a placebo pill.
Who this trial is for. This trial is for people with an IDH gene change: A small change in a tumor's IDH gene. Tumors with this change often grow more slowly and may respond to different treatments. Your pathology report says whether your tumor has it. See the glossary astrocytoma, WHO Grade 2 or 3, who have finished their first round of chemotherapy and radiation. Half of the people take vorasidenib by mouth once a day, at a dose of 40 mg. The other half take a matching placebo pill. No one involved knows which pill a person is getting.
Where it stands. There are no results yet. The trial is measuring how long people go before their tumor grows again. That answer is not in yet. This trial has not reported results.
What this means, and what it doesn't
What it could mean: If this sounds like your situation, you could ask your care team about it. They know your case and can tell you whether it is worth looking into. Whether someone can join is decided by the trial team.
What it doesn't mean: This does not mean vorasidenib works. A trial is a test, not a proven treatment. Being in a trial is not a guarantee that you will do better, and some people in this trial get a placebo. It is not a promise of a cure.
Source: ClinicalTrials.gov, August 11, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.